While MSTN inhibition does not address the underlying gene mutations responsible for these diseases, it is anticipated to offer a universal approach to treating muscle wasting that does not rely on correcting individual molecular defects, which can vary between patients and types of muscular dystrophy. Here, MSTN is linked to muscular dystrophy.